These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 36369498)
1. New-onset Evans syndrome in a patient with SLE post SARS-CoV2 mRNA vaccination. Ng TYM; Teo WZY; Ng TYM; Teng GG Ann Hematol; 2023 Jan; 102(1):235-236. PubMed ID: 36369498 [No Abstract] [Full Text] [Related]
2. Systemic Lupus Erythematosus and COVID-19. Pappa M; Panagiotopoulos A; Thomas K; Fanouriakis A Curr Rheumatol Rep; 2023 Oct; 25(10):192-203. PubMed ID: 37477841 [TBL] [Abstract][Full Text] [Related]
3. Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus. Yoshida T; Tsuji H; Onishi A; Takase Y; Shirakashi M; Onizawa H; Hiwa R; Kitagori K; Akizuki S; Nakashima R; Tanaka M; Yoshifuji H; Morinobu A Lupus Sci Med; 2022 Aug; 9(1):. PubMed ID: 35961691 [TBL] [Abstract][Full Text] [Related]
4. Hesitancy for SARS-CoV-2 vaccines and post-vaccination flares in patients with systemic lupus erythematosus. Mok CC; Chan KL; Tse SM Vaccine; 2022 Sep; 40(41):5959-5964. PubMed ID: 36085256 [TBL] [Abstract][Full Text] [Related]
5. Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis. Wang P; Ni J; Chu YY; Chen QQ; Wu GC; Fang Y; Chen C; Zhang RD; Jiang LQ; Zhao Y; Fang X; He J; Wang DG; Wang GH; Pan HF Biomed Pharmacother; 2022 Jun; 150():112997. PubMed ID: 35486976 [TBL] [Abstract][Full Text] [Related]
6. Lupus, vaccinations and COVID-19: What we know now. Mason A; Anver H; Lwin M; Holroyd C; Faust SN; Edwards CJ Lupus; 2021 Sep; 30(10):1541-1552. PubMed ID: 34134555 [TBL] [Abstract][Full Text] [Related]
7. Systemic lupus erythematosus flare following SARS-CoV2 infection: the implication of IFNα and anti-IFNα autoantibodies. Mageau A; Nicaise Roland P; Goulenok T; Farkh C; Charles N; Sacre K Clin Exp Rheumatol; 2022 Jul; 40(7):1450. PubMed ID: 35238761 [No Abstract] [Full Text] [Related]
8. Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review. He F; Luo Q; Lei M; Fan L; Shao X; Hu K; Qin S; Yu N; Cao J; Yang L Clin Rheumatol; 2020 Sep; 39(9):2803-2810. PubMed ID: 32725351 [TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 vaccine-triggered conversion from systemic lupus erythematosus (SLE) to bullous SLE and dipeptidyl peptidase 4 inhibitors-associated bullous pemphigoid. Nakahara Y; Yamane M; Sunada M; Aoyama Y J Dermatol; 2023 Feb; 50(2):162-165. PubMed ID: 36578130 [TBL] [Abstract][Full Text] [Related]
10. Impact of BNT162b2 mRNA anti-SARS-CoV-2 vaccine on interferon-alpha production by plasmacytoid dendritic cells and autoreactive T cells in patients with systemic lupus erythematosus: The COVALUS project. Mageau A; Tchen J; Ferré VM; Nicaise-Roland P; Descamps D; Delory N; François C; Mendes C; Papo T; Goulenok T; Charles N; Sacré K J Autoimmun; 2023 Jan; 134():102987. PubMed ID: 36563528 [TBL] [Abstract][Full Text] [Related]
11. Can the SARS-CoV-2 infection trigger systemic lupus erythematosus? A case-based review. Gracia-Ramos AE; Saavedra-Salinas MÁ Rheumatol Int; 2021 Apr; 41(4):799-809. PubMed ID: 33543338 [TBL] [Abstract][Full Text] [Related]
12. An ocular adverse event in temporal association with COVID-19 vaccination in a patient with systemic lupus erythematosus: a case report. Jin W; Tang Y; Wen C Hum Vaccin Immunother; 2021 Nov; 17(11):4102-4104. PubMed ID: 34617875 [TBL] [Abstract][Full Text] [Related]
13. New-onset Evans syndrome associated with systemic lupus erythematosus after BNT162b2 mRNA COVID-19 vaccination. Hidaka D; Ogasawara R; Sugimura S; Fujii F; Kojima K; Nagai J; Ebata K; Okada K; Kobayashi N; Ogasawara M; Imamura M; Ota S Int J Hematol; 2022 Mar; 115(3):424-427. PubMed ID: 34687421 [TBL] [Abstract][Full Text] [Related]
14. Severely impaired humoral response against SARS-CoV-2 variants of concern following two doses of BNT162b2 vaccine in patients with systemic lupus erythematosus (SLE). Mageau A; Ferré VM; Goulenok T; Charpentier C; Delory N; Francois C; Houhou-Fidouh N; Papo T; Descamps D; Sacre K Ann Rheum Dis; 2022 Aug; 81(8):1194-1196. PubMed ID: 35396228 [No Abstract] [Full Text] [Related]
15. Venous thrombosis in a systemic lupus erythematosus patient with antiphospholipid antibodies coinciding with mild Covid-19. Aguirre-Alastuey ME; Suárez-Díaz S; Rodríguez-Jerez F; Coto-Hernández R; Caminal-Montero L Lupus; 2021 Jan; 30(1):172-174. PubMed ID: 33092468 [No Abstract] [Full Text] [Related]
16. Are patients with systemic lupus erythematosus more prone to result false-positive for SARS-CoV2 serology? Elefante E; Tani C; Zucchi D; Signorini V; Ferro F; Mosca M Clin Exp Rheumatol; 2020; 38(3):577. PubMed ID: 32456766 [No Abstract] [Full Text] [Related]
17. [Relapse of lupus nephritis in temporal association with anti SARS-CoV-2 vaccination]. Muñoz LM; Bertoli AM; Rigo D; Sanchez Freytes M Medicina (B Aires); 2022; 82(6):971-973. PubMed ID: 36571541 [TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications. Heshin-Bekenstein M; Ziv A; Toplak N; Hagin D; Kadishevich D; Butbul YA; Saiag E; Kaufman A; Shefer G; Sharon O; Pel S; Elkayam O; Uziel Y Rheumatology (Oxford); 2022 Nov; 61(11):4263-4272. PubMed ID: 35179569 [TBL] [Abstract][Full Text] [Related]
20. Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series. Assawasaksakul T; Sathitratanacheewin S; Vichaiwattana P; Wanlapakorn N; Poovorawan Y; Kittanamongkolchai W RMD Open; 2021 Dec; 7(3):. PubMed ID: 34862313 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]